YOLFTbeta
Nuvation Bio Inc

Nuvation Bio Inc

NUVB · NYSE · Healthcare / Biotechnology

3.99USD-0.07 (-1.72%)

Price History

Full chart

Market Stats

Previous Close4.06
Open4.03
Day Range3.95 – 4.12
52-Week Range3.36 – 9.75
Volume3.08M
Market Cap2.02B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.44
Dividend Yield0.00%
Beta1.53
50-Day Avg6.42
200-Day Avg5.86

About

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. David T. Hung M.D.
  • Employees305
  • Headquarters1500 Broadway, New York, NY, United States, 10036, USA
  • Websitehttps://www.nuvationbio.com

Leadership

  • Dr. David T. Hung M.D.Founder, President, CEO & Chairman · b. 1958
  • Mr. Philippe Pierre SauvageCFO & Principal Financial Officer · b. 1978
  • Dr. Gary Hattersley Ph.D.Chief Scientific Officer · b. 1967
  • Mr. Moses Makunje CPAVP of Finance and Principal Accounting & Financial Officer · b. 1979
  • Dr. David C. Hanley Ph.D.Chief Technical Operations Officer · b. 1970
  • Robert DeVitaVice President of Corporate Development & Investor Relations
  • Dr. Stephen Dang Ph.D.Chief Legal Officer & Corporate Secretary
  • Ms. Stacy MarkelChief People Officer · b. 1965
  • Ms. Kerry A. WentworthChief Regulatory Officer · b. 1973
  • Ms. Colleen SjogrenChief Commercial Officer · b. 1971

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--00007.87M62.90M
Growth (%)-------+698.96%
Cost of Revenue--103.00K368.00K484.00K222.00K7.08M8.44M
Gross Profit---103.00K-368.00K-484.00K-222.00K795.00K54.46M
Gross Margin------10.10%86.58%
Operating Expense--43.45M92.95M119.25M99.60M593.42M267.52M
Operating Income-992.00K-32.10M-43.55M-93.32M-119.73M-99.82M-592.63M-213.06M
Operating Margin-------7527.33%-338.72%
EBITDA--32.09M-41.56M-86.66M-104.00M-75.58M-566.91M-189.21M
EBITDA Margin-------7200.75%-300.79%
Net Income-992.00K-33.55M-41.66M-86.85M-104.20M-75.80M-567.94M-204.63M
Net Income Margin-------7213.76%-325.31%
R&D482.67K25.11M32.60M69.04M87.81M71.29M524.19M115.11M
R&D as % of Total Revenue------6658.06%182.99%
Interest Expense000644.00K9.16M0341.00K13.68M
Interest Expense % of Total Revenue------4.33%21.75%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets158.00K120.95M221.79M776.15M672.14M621.48M540.63M594.82M
Total Liabilities902.00K3.20M6.71M30.15M17.07M16.36M76.84M289.11M
Total Equity-744.00K117.75M215.08M746.00M655.08M605.12M463.79M305.72M
Cash138.00K3.47M29.75M132.42M101.10M42.65M35.72M164.09M
Total Debt600.00K--3.06M4.26M4.01M8.91M10.15M
Net Debt462.00K-3.47M-29.75M-129.37M-96.84M-38.64M-26.81M-153.94M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-616.00K-24.43M-36.53M-68.19M-96.11M-68.00M-130.41M-173.43M
Investing Cash Flow-115.86M-115.86M-70.32M-454.67M63.46M8.92M122.70M99.52M
Financing Cash Flow800.00K143.62M133.13M625.53M1.33M628.00K331.00K202.53M
Capital Expenditure659.00K659.00K145.00K282.00K370.00K69.00K162.00K354.00K
Free Cash Flow-616.00K-25.09M-36.67M-68.47M-96.48M-68.07M-130.57M-173.78M
FCF to OCF100.00%102.70%100.40%100.41%100.38%100.10%100.12%100.20%

Earnings

Report DateAug 14, 2020Nov 16, 2020Mar 11, 2021May 17, 2021Aug 12, 2021Nov 10, 2021Feb 28, 2022May 9, 2022Aug 4, 2022Nov 3, 2022Mar 15, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 29, 2024May 14, 2024Aug 5, 2024Nov 6, 2024Feb 26, 2025May 7, 2025Aug 7, 2025Nov 3, 2025Mar 2, 2026May 4, 2026Aug 6, 2026Nov 2, 2026
EPS Estimate0.00--0.05-0.06-0.10-0.10-0.12-0.13-0.11-0.15-0.11-0.06-0.08-0.08-0.10-0.05-0.05-0.10-0.12-0.12-0.17-0.17-0.09-0.04-0.15-0.12
EPS Actual0.00-0.04-0.04-0.11-0.08-0.09-0.12-0.08-0.14-0.11-0.10-0.08-0.07-0.06-0.06-0.04-1.85-0.12-0.12-0.13-0.17-0.16-0.110.01-0.15-
Surprise--20.00%-83.33%20.00%10.00%0.00%38.46%-27.27%26.67%9.09%-33.33%12.50%25.00%40.00%20.00%-3600.00%-20.00%2.92%-8.33%0.00%5.88%-22.22%123.15%0.00%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hours-After-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap2.02B
Enterprise Value1.73B
Trailing P/E0.00
Forward P/E0.00
Price / Sales11.86
Price / Book8.44
EPS-0.44
Book Value0.726
Revenue (TTM)169.90M
Gross Profit (TTM)149.81M
EBITDA-135.48M
Profit Margin-88.19%
Operating Margin-161.06%
Return on Equity-47.81%
Return on Assets-12.36%
Shares Outstanding350.12M
Shares Float263.65M
Beta1.53
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 13.10
  • Strong Buy
    4
  • Buy
    3